Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDIXMAE215)
  Drug Name Busulfan Drug Info Golimumab Drug Info
  Drug Type Small molecule Monoclonal antibody
  Therapeutic Class Antineoplastics Tnf Alfa Inhibitors

 Mechanism of Busulfan-Golimumab Interaction (Severity Level: Major)
     Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Busulfan Golimumab
      Mechanism Immunosuppressive effects Immunosuppressive effects
      Key Mechanism Factor 1
Factor Name Immunosuppressive effects
Factor Description Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
      Mechanism Description
  • Additive immunosuppressive effects by the combination of Busulfan and Golimumab 

Recommended Action
      Management Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.

References
1 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
2 Product Information. Enbrel (etanercept). Wyeth-Ayerst Laboratories, Philadelphia, PA.
3 Product Information. Humira (adalimumab). Abbott Pharmaceutical, Abbott Park, IL.
4 Product Information. Remicade (infliximab). Centocor Inc, Malvern, PA.
5 Product Information. Simponi (golimumab). Centocor Inc, Malvern, PA.
6 FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. ".